One Year Post-Exclusivity
Adverse Event Review:
Imiquimod
Pediatric Advisory Committee Meeting
November 18, 2008

Amy M. Taylor, MD, MHS, FAAP
Medical Officer
Pediatric and Maternal Health Staff
Office of New Drugs
Food and Drug Administration

Background Drug Information

• **Drug:** Aldara™ (Imiquimod) Topical Cream
• **Therapeutic Category:** immune response modifier
• **Sponsor:** Graceway Pharmaceuticals, LLC
• **Original Market Approval:** February 27, 1997
• **Pediatric Exclusivity Granted:** December 13, 2006
## Background Drug Information

### Indications:
- Treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent **adults**
- Treatment of biopsy confirmed primary superficial basal cell carcinoma in immunocompetent **adults**;
- Treatment of external genital and perianal warts/condyloma acuminata in patients **12 years or older**
- Limitations of Use: Studies in children ages 2 to 12 years with molluscum contagiosum (MC) failed to demonstrate efficacy

### Dosage:
- Actinic keratosis: 2 times per week x 16 weeks
- Superficial basal cell carcinoma: 5 times per week x 6 weeks
- External genital warts: 3 times per week until cleared (maximum 16 weeks)
Background Drug Use Information

Pediatric use

- Aldara™ prescriptions in the pediatric population (ages 0-16 years) accounted for approximately 21% of total dispensed Aldara™ prescriptions*
- Of the prescriptions dispensed to pediatric patients, 40% were dispensed to patients aged 6-10 years and 38% dispensed to patients aged 11-16 years
- Top diagnoses** – viral warts and MC

**Source: SDI Physician Drug and Diagnosis Audit, Years 2005 – 2007. Data Extracted 6-2008

Exclusivity Studies

Pharmacokinetic study result:

- Absorption of imiquimod following topical application in pediatric patients was comparable to adults
Exclusivity Studies

Efficacy

• Two double-blind, vehicle-controlled safety and efficacy studies in 702 pediatric patients age 2 to 12 years with MC
  – 470 patients exposed to Aldara™
  – Treatment was up to 16 weeks

Exclusivity Studies

Efficacy results:

• Since the vehicle clearance rates were higher than Aldara™, these studies failed to demonstrate efficacy

• No indication for molluscum contagiosum granted

• Clearance rates
  – Study 1 – Aldara™ (24%); vehicle (26%)
  – Study 2 – Aldara™ (24%); vehicle (28%)
Exclusivity Studies

Safety results:
- In general, adverse events in the Aldara™ group resembled those seen in studies with adults
- The most frequently reported possibly or probably related adverse event was application site reaction (31% in Aldara™ group and 20% in vehicle group)
- A decrease in WBC and absolute neutrophil count was observed

Exclusivity Studies

Safety results (continued):
- Severe local reactions reported in Aldara™ group
  - Erythema (28%)
  - Edema
  - Scabbing/crusting
  - Flaking/scaling
  - Erosion
  - Weeping/exudate
Exclusivity Studies
Labeling Changes

Labeling Sections Changed
Highlights Section
– Indications and Usage
  • Limitations of Use
Section 1 Indications and Usage
– 1.4 Limitation of Use
Section 8 Use in Specific Populations
– 8.4 Pediatric Use

Details of Specific Labeling Changes

Section 1 Indications and Usage
– 1.4 Limitations of Use: Studies in children 2 to 12 years with MC failed to demonstrate efficacy
Exclusivity Studies
Labeling Changes

Details of Specific Labeling Changes continued

Section 8 Use in Specific Populations
8.4 Pediatric Use

- A description of the two efficacy studies and results
- Adverse events observed during the clinical studies, including incidence of severe local reactions
- A description of the pharmacokinetic study and results including extent of systemic absorption and decrease in median WBC/Absolute Neutrophil Count

Pediatric Adverse Events in 1 Year Post Exclusivity Period

<table>
<thead>
<tr>
<th>Crude Counts(^1) of AERS Reports for All Sources from Date Pediatric Exclusivity Was Granted (12/13/2006 to 1/13/2008) (US counts in parentheses)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults (≥ 17 yrs.)</td>
</tr>
<tr>
<td>All reports (US)</td>
</tr>
<tr>
<td>Serious(^2) (US)</td>
</tr>
<tr>
<td>Death (US)</td>
</tr>
<tr>
<td>Pediatrics (0-16 yrs.)</td>
</tr>
<tr>
<td>All reports (US)</td>
</tr>
<tr>
<td>Serious(^2) (US)</td>
</tr>
<tr>
<td>Death (US)</td>
</tr>
<tr>
<td>Age unknown (Null Values)</td>
</tr>
<tr>
<td>All reports (US)</td>
</tr>
<tr>
<td>Serious(^2) (US)</td>
</tr>
<tr>
<td>Death (US)</td>
</tr>
<tr>
<td>Total</td>
</tr>
<tr>
<td>All reports (US)</td>
</tr>
<tr>
<td>Serious(^2) (US)</td>
</tr>
<tr>
<td>Death (US)</td>
</tr>
</tbody>
</table>

\(^1\) May include duplicates
\(^2\) Serious adverse drug experience per regulatory definition (CFR 314.80), which includes death, life threatening, hospitalization, disability, and congenital anomaly
Pediatric Adverse Events Since Marketing Approval

Crude Counts1 of AERS Reports for All Sources from Marketing Approval Date to January 13, 2008 (US counts in parentheses)

<table>
<thead>
<tr>
<th></th>
<th>All reports (US)</th>
<th>Serious2 (US)</th>
<th>Death (US)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults (≥ 17 yrs)</td>
<td>1,289 (1,222)</td>
<td>166 (84)</td>
<td>14 (5)</td>
</tr>
<tr>
<td>Pediatrics (0-16 yrs.)</td>
<td>84 (79)</td>
<td>12 (11)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Age unknown (Null values)</td>
<td>193 (159)</td>
<td>20 (8)</td>
<td>1 (0)</td>
</tr>
<tr>
<td>Total</td>
<td>1,566 (1,360)</td>
<td>198 (102)</td>
<td>16 (5)</td>
</tr>
</tbody>
</table>

1May include duplicates
2Serious adverse drug experience per regulatory definition (CFR 314.80), which includes death, life threatening, hospitalization, disability, and congenital anomaly

Pediatric Uses Reported with Adverse Events Since Marketing Approval

Viral Warts (49%)
Molluscum Contagiosum (24%)
Warts and Common Warts (7%)
Genital Warts (6%)
Plantar Warts (3%)
Alopecia (3%)
Venereal Warts (1%)
Herpes (1%)
Actinic Keratosis (1%)
Not Reported (5%)

*Approved uses are underlined
Pediatric Adverse Events Since Marketing Approval

<table>
<thead>
<tr>
<th>Crude Counts(^1) of AERS Reports for All Sources from Marketing Approval Date to January 13, 2008 (US counts in parentheses)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults ((\geq 17) yrs)</td>
</tr>
<tr>
<td>All reports (US)</td>
</tr>
<tr>
<td>Serious(^2) (US)</td>
</tr>
<tr>
<td>Death (US)</td>
</tr>
<tr>
<td>Pediatrics (0-16 yrs.)</td>
</tr>
<tr>
<td>All reports (US)</td>
</tr>
<tr>
<td>Serious(^2) (US)</td>
</tr>
<tr>
<td>Death (US)</td>
</tr>
<tr>
<td>Age unknown (Null values)</td>
</tr>
<tr>
<td>All reports (US)</td>
</tr>
<tr>
<td>Serious(^2) (US)</td>
</tr>
<tr>
<td>Death (US)</td>
</tr>
<tr>
<td>Total</td>
</tr>
<tr>
<td>All reports (US)</td>
</tr>
</tbody>
</table>

\(^1\)May include duplicates

\(^2\)Serious adverse drug experience per regulatory definition (CFR 314.80), which includes death, life threatening, hospitalization, disability, and congenital anomaly

Pediatric Deaths Since Market Approval

(N=1)

16 year old female committed suicide by gunshot while on 3\(^{rd}\) month of second course of imiquimod (12.5 mg) three times weekly for viral warts. Total treatment duration 31 weeks. No known history of depression. This is a labeled event.
Pediatric Adverse Events Since Marketing Approval

Crude Counts\(^1\) of AERS Reports for All Sources from Marketing Approval Date to January 13, 2008 (US counts in parentheses)

<table>
<thead>
<tr>
<th></th>
<th>All reports (US)</th>
<th>Serious(^2) (US)</th>
<th>Death (US)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults (≥17 yrs)</td>
<td>1,289 (1,222)</td>
<td>166 (84)</td>
<td>14 (5)</td>
</tr>
<tr>
<td>Pediatrics (0-16 yrs.)</td>
<td>84 (79)</td>
<td>12 (11)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Age unknown (Null values)</td>
<td>193 (159)</td>
<td>20 (8)</td>
<td>1 (0)</td>
</tr>
<tr>
<td>Total</td>
<td>1,566 (1,360)</td>
<td>198 (102)</td>
<td>16 (5)</td>
</tr>
</tbody>
</table>

\(^1\)May include duplicates
\(^2\)Serious adverse drug experience per regulatory definition (CFR 314.80), which includes death, life threatening, hospitalization, disability, and congenital anomaly

Serious Pediatric Adverse Events Since Market Approval (N=12)

**Neurologic (n=3)**
- Seizures (n=2); labeled
- Temporary paralysis (n=1); labeled

**Congenital Anomaly (n=2)**
- Undecended testicles, GU reflux, ASD, VSD; unlabeled
- Hirschsprung’s disease; unlabeled

**Hematologic (n=1)**
- Thrombocytopenia purpura; labeled
Serious Pediatric Adverse Events Since Market Approval

Localized reactions (n=6) labeled

- 7 year old female with a history of cerebral palsy after two applications for genital warts developed extreme swelling and inability to void necessitating catheterization in the emergency room. Patient also diagnosed with viral infection after developing a sore throat and low grade fever.
- 15 year old female with burning blisters, swelling and inability to void after one application for genital warts. Treated with topical lidocaine.
- 4 year old female with burning pain and inability to void, fever, and flu-like symptoms after 3 days of treatment (daily application) for herpes. Patient was hospitalized 2 days later.

- 15 year old female with skin burns, blisters, pain upon urination, fever and fatigue after 5 days of treatment (1/2 packet 3 times/week) for genital warts. Patient was hospitalized and treated with antibiotics for the skin burns and blisters
- 16 year old female with burning, erosions, and ulcerations after 3 days of treatment (1 packet daily) for genital warts. Patient was hospitalized after developing fever, increase WBC (14,000), and flu-like symptoms.
- 10 year old male with an application site abscess requiring incision and drainage and antibiotics after 1 month of treatment (unknown dosage every other day for 2 weeks and daily for 2 weeks) for MC.
Current Labeling

17. Patient Counseling Information

17.6 Patients Being Treated for External Genital Warts

– Female patients should take special care if applying the cream at the opening of the vagina because local skin reactions on the delicate moist surfaces can result in pain or swelling and may cause difficulty in passing urine.

Summary: Imiquimod

• Pediatrics accounts for 21% of Aldara™ use*
• Despite studies showing lack of efficacy, off-label use is common including treatment of MC
• Pediatric female patients have reported inability to void secondary to severe local reactions during use in the genital area
  – The Review Division is planning to update this adverse reaction in the labeling.

(Source: SDI Vector One® National, Years 2005 – 2007. Data Extracted 6-2008.)
Question for the Committee

• In addition to planning to update the labeling related to severe local reactions in females with use in the genital area, FDA will continue its standard, ongoing safety monitoring for imiquimod.

• Does the Advisory Committee concur?

Acknowledgements

OSE
• Kendra Worthy, Pharm.D
• Vicky Borders-Hemphill, Pharm.D.
• Laura Governale, Pharm.D., M.B.A
• Marilyn Pitts, Pharm.D
• Mark Avigan, M.D., C.M.

DDDP
• Brenda Carr, M.D.
• Jill Lindstrom, M.D.
• Margo Owens

PMHS
• Denise Pica-Branco, Ph.D
• Susan Cummins, M.D., M.P.H.
• Hari Cheryl Sachs, M.D.
• Lisa Mathis, M.D.

OPT
• Debbie Avant, R.Ph.
• Suzanne Malli, B.A., B.S.N.
• Judith Cope, M.D., M.P.H.
• Dianne Murphy, M.D.